title: Prediction of pathological complete response to neoadjuvant chemotherapy by magnetic resonance imaging in breast cancer patients.
abstract: The purpose of this study was to evaluate whether the baseline breast MRI findings would be useful for the prediction for pathological complete response (pCR) by breast cancer patients to neoadjuvant chemotherapy. Primary breast cancer patients (stage II-III) preoperatively treated with sequential paclitaxel (12 cycles) and fluorouracil, epirubicin, and cyclophosphamide (4 cycles), followed by surgery were retrospectively enrolled, and 229 patients were eligible. Before chemotherapy, breast MRI studies were performed. Breast tumors were dichotomized into round + oval and irregular types based on MRI morphology. The round + oval tumors showed a significantly higher pCR rate than the irregular tumors (42.0% vs 17.3%; P < 0.001). In addition, PAM50 analysis revealed that basal and HER2-enriched tumors were significantly more prevalent among round + oval than irregular type tumors (P = 0.015). Baseline MRI morphology appears to be a significant predictor for pCR. The higher rate of the basal and HER2-enriched tumors among the round + oval tumors may explain their better chemo-sensitivity.
authors: Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
authors: Shintaro
authors: S
authors: Michishita
authors: Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan. Electronic address: kimsj@onsurg.med.osaka-u.ac.jp.
authors: Seung Jin
authors: SJ
authors: Kim
authors: Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
authors: Kenzo
authors: K
authors: Shimazu
authors: Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
authors: Yoshiaki
authors: Y
authors: Sota
authors: Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
authors: Yasuto
authors: Y
authors: Naoi
authors: Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
authors: Naomi
authors: N
authors: Maruyama
authors: Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
authors: Naofumi
authors: N
authors: Kagara
authors: Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
authors: Masafumi
authors: M
authors: Shimoda
authors: Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
authors: Atsushi
authors: A
authors: Shimomura
authors: Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
authors: Shinzaburo
authors: S
authors: Noguchi
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D018275:Carcinoma, Lobular / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D015331:Cohort Studies; D003520:Cyclophosphamide / Q000008:administration & dosage; D003661:Decision Support Techniques; D015251:Epirubicin / Q000008:administration & dosage; D047628:Estrogen Receptor alpha / Q000378:metabolism; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008279:Magnetic Resonance Imaging; D008408:Mastectomy; D015412:Mastectomy, Segmental; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D012189:Retrospective Studies; D016896:Treatment Outcome; D047368:Tumor Burden; D055815:Young Adult
chemical_list: D003520:Cyclophosphamide; D015251:Epirubicin; D047628:Estrogen Receptor alpha; D005472:Fluorouracil; D017239:Paclitaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; D011980:Receptors, Progesterone; C506487:ESR1 protein, human; C508053:ERBB2 protein, human
keywords: Intrinsic subtype; MRI morphology; Neoadjuvant chemotherapy; Predictor; pCR